Fennell DA - Search Results

1

Gastrointestinal haemorrhage associated with free-base (crack) cocaine.

Fennell DA, Gandhi SS, Prichard BN. Fennell DA, et al. Postgrad Med J. 1995 Jun;71(836):377-8. doi: 10.1136/pgmj.71.836.377. Postgrad Med J. 1995. PMID: 7644406 Free PMC article.

2

Quantitative antisense dose-response relationships: mathematical modeling of antisense action under steady-state conditions.

Fennell DA. Fennell DA. Antisense Nucleic Acid Drug Dev. 1997 Feb;7(1):49-53. doi: 10.1089/oli.1.1997.7.49. Antisense Nucleic Acid Drug Dev. 1997. PMID: 9055039

3

Ganetespib in Combination with Pemetrexed-Platinum Chemotherapy in Patients with Pleural Mesothelioma (MESO-02): A Phase Ib Trial.

Fennell DA, Danson S, Woll PJ, Forster M, Talbot D, Child J, Farrelly L, Sharkey A, Busacca S, Ngai Y, Hackshaw A, Wheeler GM. Fennell DA, et al. Clin Cancer Res. 2020 Sep 15;26(18):4748-4755. doi: 10.1158/1078-0432.CCR-20-1306. Epub 2020 Jul 15. Clin Cancer Res. 2020. PMID: 32669375 Free article. Clinical Trial.

4

Kinetics of the human leucocyte Na(+)-H+ antiport in essential hypertension.

Ng LL, Fennell DA, Dudley C. Ng LL, et al. Among authors: fennell da. J Hypertens. 1990 Jun;8(6):533-7. doi: 10.1097/00004872-199006000-00006. J Hypertens. 1990. PMID: 2165087

5

A dynamical systems model to simulate the perturbation kinetics of gene expression by antisense oligonucleotides.

Fennell DA, Cotter FE. Fennell DA, et al. J Theor Biol. 2001 Mar 7;209(1):103-12. doi: 10.1006/jtbi.2000.2250. J Theor Biol. 2001. PMID: 11237574

6

Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials.

Fennell DA, Parmar A, Shamash J, Evans MT, Sheaff MT, Sylvester R, Dhaliwal K, Gower N, Steele J, Rudd R. Fennell DA, et al. J Clin Oncol. 2005 Jan 1;23(1):184-9. doi: 10.1200/JCO.2005.07.050. J Clin Oncol. 2005. PMID: 15625372

7

Phase II trial of vinorelbine and oxaliplatin as first-line therapy in malignant pleural mesothelioma.

Fennell DA, C Steele JP, Shamash J, Sheaff MT, Evans MT, Goonewardene TI, Nystrom ML, Gower NH, Rudd RM. Fennell DA, et al. Lung Cancer. 2005 Feb;47(2):277-81. doi: 10.1016/j.lungcan.2004.08.005. Lung Cancer. 2005. PMID: 15639727 Clinical Trial.

8

Stochastic modelling of apoptosis kinetics.

Fennell DA, Pallaska A, Corbo M, Cotter FE. Fennell DA, et al. Apoptosis. 2005 Mar;10(2):447-52. doi: 10.1007/s10495-005-0818-2. Apoptosis. 2005. PMID: 15843905

9

In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion.

Szlosarek PW, Klabatsa A, Pallaska A, Sheaff M, Smith P, Crook T, Grimshaw MJ, Steele JP, Rudd RM, Balkwill FR, Fennell DA. Szlosarek PW, et al. Among authors: fennell da. Clin Cancer Res. 2006 Dec 1;12(23):7126-31. doi: 10.1158/1078-0432.CCR-06-1101. Clin Cancer Res. 2006. PMID: 17145837

10

Efficacy and safety of first- or second-line irinotecan, cisplatin, and mitomycin in mesothelioma.

Fennell DA, Steele JP, Shamash J, Evans MT, Wells P, Sheaff MT, Rudd RM, Stebbing J. Fennell DA, et al. Cancer. 2007 Jan 1;109(1):93-9. doi: 10.1002/cncr.22366. Cancer. 2007. PMID: 17146783 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

212 results

Search Page

Filters